Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06947395 · ClinicalTrials.gov registry record
Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)
A clinical trial of Pancreatic Cancer and Cancer of the Pancreas, sponsored by Immunovia.
- Completed
- Registry status
- 386
- Enrollment target
- 6
- Study locations
NCT06947395: Completed study of Pancreatic Cancer and Cancer of the Pancreas, sponsored by Immunovia.
NCT06947395 is a study of Pancreatic Cancer and Cancer of the Pancreas that has completed, run by Immunovia. The registered enrollment target is 386 participants, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target. The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06947395, a study of Pancreatic Cancer and Cancer of the Pancreas, has completed, sponsored by Immunovia.
- COMPLETED
- Registry status
- 386 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of disease due to familial/genetic history or clinical symptoms.
Primary Outcome
Determine the sensitivity of PancreaSure in the classification of serum samples from patients diagnosed with PDAC as positive for PDAC, in a study sample containing both PDAC and control samples.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PancreaSure
Study Locations (6)
Arizona
- HonorHealth Clinical Research Institute - Scottsdale
New York
- New York University Langone Health - New York
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Tennessee
- Regional One Health - Memphis
Texas
- UT Southwestern Medical Center - Dallas
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2025-02-11 |
| Est. Completion | 2025-04-07 |
What the finished NCT06947395 record still lists
NCT06947395 is an observational study that tracks outcomes without assigning an intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target.
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PancreaSure is the first listed.
NCT06947395 lists 6 locations in 6 states (Arizona, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06947395 about?
NCT06947395 is a clinical study titled "Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)". This is a case-control study to clinically validate the performance of PancreaSure, a protein biomarker test, to differentiate Stage I and Stage II pancreatic ductal adenocarcinoma (PDAC) patient samples from samples acquired from control patients not diagnosed with PDAC but at increased risk of dis...
What is the current status of trial NCT06947395?
This trial is currently completed. The enrollment target is 386 participants. The study started on 2025-02-11. Estimated completion is 2025-04-07.
What conditions does trial NCT06947395 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Cancer of the Pancreas, Pancreas Neoplasms, Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II.
What interventions are being tested in trial NCT06947395?
The interventions under investigation include: PancreaSure (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06947395?
This trial is sponsored by Immunovia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06947395 being conducted?
This trial has 6 study locations across Arizona, New York, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06947395's enrollment target sits among peer trials
386 43rd of 278 higher than 236 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI